Imaging in Oncology Clinical Trials: Precision, Speed, and Global Scale
Whether your study involves RECIST, Lugano, mRECIST, RANO or other oncology imaging endpoints, radioligand therapies, or complex clinical biomarker integration, our scalable medical imaging oncology services deliver the expertise and infrastructure needed to meet the highest data standards and regulatory rigor.
From Phase I oncology trials to pivotal registration studies, our imaging core lab supports every step of your imaging workflow. For trials exploring advanced endpoints, we offer cutting-edge image analysis capabilities, including radiomics and AI-powered pipelines, enabling deeper insights into tumor response and progression.
Why Sponsors Choose Perceptive for Oncology Imaging Services
Clinical Trial Scientific Imaging Leadership
Imaging strategy and study designs are led by board-certified radiologists and oncology imaging experts who bring decades of experience in oncology clinical development and regulatory engagement.
Standard-of-Care and Advanced Therapy Imaging
We deliver the precision and flexibility you need, whether your study involves conventional CT and MRI scans or specialized imaging for novel mechanisms of action like radioligand therapies and antibody drug conjugates (ADC).
Therapeutic Breadth in Clinical Imaging
We support the whole range of oncology indications — including breast cancer, renal cell carcinoma, lung cancer, CNS tumors and hematologic malignancies — with tailored imaging strategies that reflect the nuances of each disease area.
Faster, More Reliable Insights
Our proprietary, technology-enabled platform streamlines image quality control, reader performance monitoring, and data delivery — delivering greater insights to help inform confident decision making, faster.
Regulatory Excellence in Cancer Research
With zero observations across FDA, EMA, and NMPA inspections over the past decade, our inspection readiness program and quality systems are proven to meet global regulatory expectations.
Global Ops & Scalability with APAC Presence
Whether your study is fast-tracked at the start or becomes accelerated later, trust Perceptive’s scalable operational model and global employees to deliver harmonized, 24/7 support that scales to meet timelines and drive your trial’s success.
Solid Tumor Clinical Trial Imaging Services
Perceptive Imaging brings significant experience in solid tumor clinical trial imaging, supporting all phases of clinical development and helping sponsors meet global regulatory expectations, across both standard-of-care and advanced medical imaging.
Our scientific and operational teams work in lockstep to ensure imaging strategies are aligned with regulatory expectations from day one — reducing risk, accelerating timelines, and supporting breakthrough designations.
Contact us to discuss other capabilities not listed below, or other, emerging solutions for your study.
Our expertise includes, but is not limited to:
|
Indications
|
Response Criteria
|
Molecule Types
|
Modalities
|
Advanced Image Analysis
|
|---|---|---|---|---|
| Lung Cancer | RECIST 1.1 | Small molecules | CT | Radiomics |
| Breast Cancer | iRECIST | Radioligand therapies | MRI | Dosimetry |
| Colorectal Cancer | irRECIST | Proteins incl. ADCs | X-ray | Automated PSMA Segmentation |
| Prostate Cancer | iRC | Gene therapies | Bone Scan | |
| HCC | mRECIST | Cell therapies | PET | |
| Melanoma | PERCIST | Peptides | SPECT | |
| Ovarian Cancer | PCWG3 | Vaccines | Mammography | |
| RCC | RANO Variants | RNA-based therapies | Photography | |
| Primary Brain Tumors |
Scientific Leadership

Souhil Zaim, MD
Vice President, Medical Services
Vice President of Medical Services, a board-certified radiologist with over 25 years of experience in medical imaging and a recognized expert in imaging biomarkers across therapeutic areas.

Oliver Bohnsack, MD, PhD, MBA
Vice President, Medical Imaging
A recognized authority in clinical trial imaging for more than 20 years and a co-author of both irRC and irRECIST. His leadership ensures that every imaging strategy is grounded in the latest science and regulatory expectations.
RLT may be new to some, but at Perceptive, nuclear medicine is in our DNA
We’re pioneering radiopharmacuticals.
Malignant Hematology Imaging Services
Multiple Myeloma Imaging, Leukemia Imaging, Lymphoma Imaging, and Myelofibrosis Imaging
Hematologic malignancy trial imaging is especially complex. Multiple Myeloma, Lymphoma, and Leukemia trials require not only clinical trial imaging, but also the integration of complex clinical data to support efficacy endpoints. And Myelofibrosis trials require multiple imaging modalities and specialized expertise to demonstrate treatment effect with confidence.
Having supported over 370 malignant hematology trials and 70 regulatory approvals – including 17 breakthrough therapies, our imaging core lab services have been proven to meet these challenges head on. The result? You don’t have to worry about gaps or delays, and you gain confidence that your imaging data is high-quality and regulator-ready.
Our experience spans across:
As trial complexity increases, so does the likelihood for things to go wrong – but not with Perceptive Imaging.
We have the people, processes, and infrastructure to keep your trial on track. Our integrated imaging and clinical data workflows are proven, scalable, regulator-aligned, and ready to meet the most complex trial needs.
Scientific Leadership

Souhil Zaim, MD
Vice President, Medical Services
Vice President of Medical Services, a board-certified radiologist with over 25 years of experience in medical imaging and a recognized expert in imaging biomarkers across therapeutic areas.

Rudresh Jarecha, MD
Senior Medical Director and Head of Hemato-Oncology
Senior Medical Director and Head of Hemato-Oncology, with two decades of experience in clinical development and deep specialization in hematologic malignancies.
Frequently Asked Questions
1. What medical imaging services does Perceptive offer for oncology clinical trials?
We provide comprehensive imaging services for oncology trials, including tumor response assessments (e.g. RECIST, mRECIST, RANO), radioligand therapy support, advanced image analysis (radiomics/AI), and biomarker integration across phases I to pivotal registration.
2. How does Perceptive ensure regulatory readiness in oncology imaging studies?
Perceptive maintains rigorous quality systems and inspection readiness programs with zero observations over the past decade in FDA, EMA, and NMPA inspections. We align imaging strategy and data workflows to global regulatory expectations from study planning through submission.
3. What tumor types and modalities are supported in your oncology imaging core lab?
We support a wide range of solid tumors (e.g. lung, breast, colorectal, CNS, RCC) and hematologic malignancies (e.g. multiple myeloma, lymphoma, leukemia), using CT, MRI, PET, SPECT, bone scan, mammography, and more.
4. Can Perceptive handle complex endpoints and advanced therapies like ADCs or radiopharmaceuticals?
Yes. we have experience designing imaging strategies for advanced mechanisms like antibody-drug conjugates (ADCs), gene and cell therapies, and radioligand therapies, and incorporating advanced endpoints, dosimetry, and imaging biomarker integration.
5. What sets Perceptive apart as a global oncology imaging CRO?
Key differentiators include eadership by industry-recognized, therapeutically-aligned scientific experts, scalable global operations (including APAC presence), streamlined image QC and centralized platform, and deep experience across >1,800 trials and >300 regulatory approvals.
What’s new at Perceptive Imaging
Imaging Excellence in Hematology Trials: From Protocol through Delivery
Read more
How Can We Help?
Reach out today and one of our solution experts will be in touch to learn about your specific needs.
"*" indicates required fields
Stay Updated
Never miss a beat.
Sign up to receive emails covering industry news and useful content to help you advance clinical development.